Promethazine
- Generic Name
- Promethazine
- Brand Names
- Phenadoz, Phenergan, Promethazine DM, Promethegan
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N2S
- CAS Number
- 60-87-7
- Unique Ingredient Identifier
- FF28EJQ494
Overview
Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of phenothiazine that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting. Promethazine was granted FDA approval before 29 March 1951.
Background
Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of phenothiazine that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting. Promethazine was granted FDA approval before 29 March 1951.
Indication
Promethazine tablets and suppositories are indicated to treat rhinitis, allergic conjunctivitis, allergic reactions to blood or plasma, dermographism, anaphylactic reactions, sedation, nausea, vomiting, pain, motion sickness, and allergic skin reactions. Promethazine cough syrup with phenylephrine and codeine is indicated to relieve cough and upper respiratory symptoms, and nasal congestion associated with allergy or the common cold.
Associated Conditions
- Allergic Conjunctivitis (AC)
- Allergic urticaria
- Anaphylaxis
- Cough
- Dermographism
- Motion Sickness
- Nasal Congestion
- Postoperative pain
- Seasonal Allergic Rhinitis
- Vasomotor Rhinitis
- Acute Allergic Reactions
- Dry cough
- Perioperative nausea and vomiting
- Upper respiratory symptoms
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.